Technology
Health
Biotechnology
Unity Biotechnology
$8.479876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$8.47
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.43 (5.35%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell UBX and other stocks, options, ETFs, and crypto commission-free!
About
Unity Biotechnology, Inc. operates as a biotechnology company engaged in the research and development of therapeutics to extend the human health span. The company was founded by Nathaniel David, Jan van Deursen, Judith Campisi and Daohong Zhou in March 2009 and is headquartered in Brisbane, CA.
Employees
106
Headquarters
Brisbane, California
Founded
2009
Market Cap
363.26M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
184.45K
High Today
$8.58
Low Today
$8.13
Open Price
$8.13
Volume
72.47K
52 Week High
$24.56
52 Week Low
$7.39
Collections
Technology
Health
Biotechnology
Research And Development
Therapy
2018 IPO
US
North America
News
Associated PressMay 8
UNITY Biotechnology, Inc. Reports First Quarter 2019 Financial Results
SAN FRANCISCO, May 08, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today reported first quarter 2019 financial results. UNITY also announced the last study visit for the last subject enrolled in the Phase 1 study of UBX0101 in patients with osteoarthritis of the knee occurred in April 2019. UNITY remains on track to report initial study results in the secon...
Price Paid on Robinhood
31% Lower
Right Now
52 Week Low
$7.39
Average Price Paid
$12.19
52 Week High
$24.56
Earnings
-$4.69
-$3.27
-$1.85
-$0.43
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.51 per share
Actual
-$0.44 per share